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 Abstract 
This systematic review synthesizes literature describing prevalence, characteristics and 
prognosis of low back-related leg pain (LBLP) patients with neuropathic pain in primary care 
and/or similar settings. Inclusion and exclusion criteria were developed and used by 
independent reviewers to screen citations for eligibility. The initial search yielded 24,948 
citations; after screening 12 studies were included. Neuropathic pain was identified by case 
ascertainment tools (n=5), by clinical history with examination (n=4), and by LBLP samples 
assumed neuropathic (n=3). Neuropathic pain prevalence varied from 19% to 80%. There 
was consistent evidence for higher back-related disability (n=3), poorer health-related 
quality of life (n=2) and some evidence for more severe depression (n=2), anxiety (n=3) and 
pain intensity (n=4) in patients with neuropathic pain. Results were less consistent when 
cases were identified through clinical history plus examination than those identified using 
case ascertainment tools. Prognosis (n=1) of LBLP patients with neuropathic pain was worse 
compared to those without, in all outcomes (leg pain intensity, leg and back-related 
disability, self-reported general health) except back pain intensity. No studies described 
prognostic factors. This systematic review highlights the evidence gap in neuropathic pain in 
LBLP in primary care, especially with respect to prognosis.  
Perspective 
Patients with low back-related leg pain may have neuropathic pain. This systematic review 
emphasises the paucity of evidence describing the characteristics and prognosis of 
neuropathic pain in this patient population. Future research investigating prognosis of these 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
3
patients with neuropathic pain is likely to contribute to better understanding and 
management.  
 
Key words 
Low back pain; leg pain; primary care; neuropathic pain; epidemiology 
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 1. Introduction 
Neuropathic pain presents as one of the most challenging pain syndromes to identify and 
treat 
52
. Patients with underlying neuropathic pain (considered to be pain caused by injury 
or disease to the somatosensory system 
55
) commonly self-report neuropathic 
characteristics such as prickling and/or burning sensations, and heat and pressure induced 
pain. The International Association for the Study of Pain (IASP) developed a grading system 
to assist researchers and clinicians to identify cases of neuropathic pain 
55
. The grading 
system proposes that a patient presenting with pain, and with a plausible clinical history 
together with relevant neurological examination findings, meets the criteria for a working 
hypothesis of possible neuropathic pain 
55
. With the addition of appropriate findings from 
diagnostic tests, a patient can meet the criteria for probable neuropathic pain. When clinical 
examination is not possible in epidemiological research, (for example, Torrance et al 
54
 and 
VanDenKerfhof et al 
60
) neuropathic case ascertainment tools use self-reported neuropathic 
characteristics (for example, Self-report version of Leeds Assessment of Neuropathic 
Symptoms and Signs (S-LANSS) 
8
 to identify, at best, possible cases of neuropathic pain 
20, 52
.  
 
Low back pain (LBP) is one of the most common presentations of neuropathic pain 
9
. 
Regardless of underlying pain mechanisms, LBP is the leading cause of disability globally and 
a major public health problem 
12
. Patients with leg pain related to their back pain (LBLP) is a 
common presentation of LBP with approximately two thirds of LBP patients seeking 
treatment in both primary and secondary care settings, reporting leg pain 
32, 37
. LBLP is 
associated with increased disability and pain, and poorer quality of life compared to LBP 
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alone 
31, 39
. There is a strong argument that research investigating the epidemiology of 
patients with LBP should distinguish those with LBLP based on their characteristics and 
prognosis 
14, 23
. 
 
LBLP is clinically diagnosed as either sciatica (otherwise known as lumbar radicular pain) or 
referred leg pain. Sciatica is characterised by leg pain that often radiates to beyond the knee 
and into the foot or toes, it may be accompanied by muscle weakness and/or reflex change 
and/or pins and needles or numbness (paraesthesia), in a specific nerve root(s) distribution 
36
. Sciatica is thought to be caused by compression of the spinal nerve root(s), most 
commonly by an intervertebral disc prolapse whereas referred leg pain is pain arising from 
structures in the back such as ligaments, discs or joints, but does not involve the spinal 
nerve(s). Mechanisms of pain are considered to be either neuropathic or if there is no injury 
or damage to the somatosensory system, the pain mechanism is deemed to be non-
neuropathic and described by the term nociceptive. Currently, sciatica is considered 
neuropathic in nature and referred leg pain is considered nociceptive. However, there is 
evidence that the underlying mechanism of LBP and LBLP comprises coexisting neuropathic 
and nociceptive mechanisms 
25
, and that at times, sciatica patients may not present with 
neuropathic pain characteristics, and patients with referred leg pain might have neuropathic 
pain 
40
.  
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The first point of contact for individuals with back pain in the UK health care system, 
including those with neuropathic pain, are primary care providers 
14
. The majority of these 
patients continue to be managed in primary rather than in secondary care 
11 
 even if they 
complain of persistent and bothersome pain. Back pain patients consult in primary care 
seeking information and treatment options for their condition, these often include 
medication options and information on prognosis 
11
. Primary care providers also act as 
gatekeepers, referring to specialist clinical settings only those patients who may require 
and/or benefit from specialist assessment and interventions. There is variation globally in 
access to primary care for individuals with back pain. Whilst patients in the UK are initially 
mainly seen by primary care providers, patients in other countries (depending on the 
structure of a country’s health system) may have direct access to specialist centres 
(secondary care) as the first point of contact, including centres with neurosurgery, 
neurology and pain expertise, although they are likely very similar in presenting 
symptomatology to those patients not seen in specialist settings, at least initially. Research 
set in primary care and in other settings that patients have direct access to, is important as 
it is likely to capture the patient population seeking care with similar low back related pain 
problems 
11
.  
 
Identification of mechanisms that underlie the development and persistence of back pain 
presentations, and the development of and testing of ways to better match treatment to 
patients, are both internationally agreed research priorities 
14
. There are specific medication 
options for patients with neuropathic pain, based on underlying mechanisms that may 
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accompany nerve damage
 20 
and these are advocated for patients (including those with 
sciatica) consulting in primary care 
43, 44
. Recognising neuropathic pain in LBLP patients in 
primary care is important as this may facilitate timely access to recommended medications, 
if deemed appropriate, which in turn may contribute to better outcomes for these patient. 
There have been attempts to identify neuropathic pain as a subgroup of LBP and LBLP 
47, 48
 
and previous systematic reviews have addressed the broader area of neuropathic pain in 
LBP 
19, 35
. Current pain research has predominantly been conducted in specialist pain centres 
often based in tertiary care. It is likely that populations of patients drawn from these 
settings are systematically different to patients in primary care and this may limit 
generalisability of these findings 
16
 to primary care consulters. The prevalence of 
neuropathic pain in LBLP patients remains unclear, as does its clinical course and factors 
associated with its prognosis, especially in primary care. It is also not clear whether the 
characteristics of LBLP patients differ in patients with and without neuropathic pain.   
Currently, there are no published reviews summarising the research evidence on the 
epidemiology of neuropathic pain in LBLP. We conducted a systematic review of studies 
examining the prevalence, characteristics and prognosis of neuropathic pain in LBLP patients 
consulting in any setting that seemed to be the first point of contact for this population. 
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2. Methods 
2.1. Protocol registration 
A protocol of this systematic review was registered and can be accessed on the PROSPERO 
international prospective register of systematic reviews (through the web address 
http://www.crd.york.ac.uk/PROSPERO/ using the registration number CRD42015023388). 
 
2.2. Search strategy 
Electronic databases MEDLINE, EMBASE, CINAHL, AMED, Web of Science Core Collection 
and TRIP were searched from inception of each database to August 2015 for studies that 
fulfilled the inclusion and exclusion criteria (see Table 1). The search was not restricted to 
specific languages. The search strategy was developed in consultation with information 
specialists and used all key words and MeSH terms to explore the most important key areas: 
LBLP, neuropathic pain, epidemiology, including key words and MeSH terms for prevalence 
and prognosis (see Supplementary Materials Table S1 for the full details of the search 
strategy used in MEDLINE). A supplementary search was carried out by bibliography 
screening and citation tracking of included studies 
28
, relevant systematic reviews and 
original studies of case identification tools 
6, 9, 24
. A search of the grey literature was carried 
out, seeking unpublished research in doctoral theses and from conference proceedings, via 
the internet search engines Google Scholar and OpenGrey. 
2.3. Data extraction  
All studies identified from the electronic databases were directly imported into online 
reference management (Endnote X7.4) and duplicates were removed. Eligible studies were 
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selected on title first by one reviewer (SH), then abstracts were screened by two 
independent reviewers (SH and SS). Full papers were retrieved and assessed if the abstract 
provided insufficient information. Disagreements were resolved by consensus. Two 
independent reviewers (SH and SS, KK or KD) extracted data from eligible studies using a 
bespoke data extraction form on: study name, authors and publication year; publication 
language; study design; setting; study population; sampling methods; definition of LBLP; 
participant characteristics; definition of neuropathic pain; method of case ascertainment for 
neuropathic pain; description of prevalence; characteristics associated with neuropathic 
pain; clinical course of condition and factors associated with prognosis. Authors were 
contacted for further data or clarification, where required. 
 
2.4. Risk of bias (quality assessment) 
Two quality assessment tools were used in this review 
29, 34
. One to appraise the evidence on 
prevalence 
34
 and the other to appraise the evidence on characteristics and prognosis 
29
. We 
used the tool developed by Hoy et al 
34
 to assess the risk of bias in prevalence studies; it 
includes ten items, four related to external validity (the assessment of whether the results 
of the study can be believed), and six related to internal validity (the assessment of how well 
the study is performed) (see supplementary materials Table S2). In this review, when 
information was insufficient to make a judgement for a particular item, the item was 
assigned as high risk of bias. Each included study was then assigned an overall risk of study 
bias as ‘low’, ‘moderate’ or ‘high’. Studies with eight or more items scored as low risk were 
considered overall to be of ‘low risk of bias’, those with six to seven items scored as low risk 
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were considered overall to be of ‘moderate risk of bias’, and those with five or fewer items 
scored as low risk were considered overall to be of ‘high risk of bias’. This method of scoring 
the overall risk of study bias has been utilised by previous systematic reviews 
2, 27, 58
. 
 
The Quality in Prognosis Studies (QUIPS) tool was used to appraise individual studies 
providing data on characteristics and prognosis (see supplementary materials Table S3). The 
reviewers assigned six different domains as having either ‘low’, ‘moderate’ or ‘high’ risk of 
bias or ‘unsure of the risk of bias, or that the domain was not relevant. The study was then 
assigned as having an overall ‘low’, ‘moderate’ or ‘high’ risk of bias. All studies, regardless of 
their quality, were included for critical appraisal and synthesis. For both tools, two 
independent reviewers (SH and SS, KK or KD) completed the quality assessment and any 
disagreements were resolved by consensus.  
 
2.5. Data analysis  
Statistical pooling was not appropriate therefore a narrative synthesis was conducted with a 
description of studies and tabulation of results 
1
. An exploration of the robustness of the 
synthesis, and of the relationships between and within studies, formed part of this narrative 
review. 
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3. Results 
3.1. Studies identified 
The search of electronic databases yielded 24,948 articles (Figure 1 shows a flow chart 
adapted from the PRISMA flow chart 
41
). An additional three articles were identified through 
other sources; two titles were retrieved from citation tracking of relevant systematic 
reviews and of original articles of case identification tools, the third title was identified 
through citation tracking of included articles. 88 full text articles were assessed for eligibility, 
just under half (n=41) were excluded because data could not be extracted on LBLP patients 
or because the population were patients with LBLP conditions clearly requiring specialist 
care (for example; failed back surgery syndrome), two articles were excluded because the 
population described consulted in tertiary care centres and were not directly comparable to 
primary care samples (Figure 1 summarises all reasons for excluded studies). Twelve full text 
articles were included in the final review and all underwent quality assessment and data 
extraction. 
 
A summary of the included studies is presented in Table 2. None of the studies included in 
this systematic review, directly aimed to estimate prevalence or describe the characteristics 
of LBLP patients with neuropathic pain. However, it was possible to extrapolate data to 
estimate prevalence of neuropathic pain in LBLP patients in seven of the studies 
3, 6, 42, 45, 46, 
57, 62
. Ten studies reported on characteristics 
6, 18, 25, 40, 42, 48, 51, 56, 57, 62
, and from the two 
studies that provided longitudinal data 
42, 48
, it was possible to derive information on 
prognosis from one study 
42
. A total of 3,457 patients were included in all twelve studies. 
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Overall, the sample sizes were small (the median sample size was 74). There was wide 
variability in the characteristics of the LBLP patient population in the included studies, with 
mixed pain severity and duration, and the classification of LBLP by some studies was closely 
associated with the definition of neuropathic pain. Two studies described characteristics of 
neuropathic pain in LBLP without a comparison group relevant to the study 
40, 51
, and one 
study described characteristics with an alternative comparison group. Defrin et al 
18
 
described neuropathic pain in LBLP patients with or without allodynia. These three studies 
were included in the review because of the relevance of the reported characteristics.  
 
Neuropathic pain was most commonly identified using case ascertainment tools, either in 
isolation 
6, 42, 45, 56, 57
 or in addition to clinical history and examination 
3, 48, 51, 62
. Three studies 
18, 25, 40
 used their definition of LBLP to assume a neuropathic component, so all patients in 
these studies were considered to have neuropathic pain. All studies were published since 
the IASP redefinition and grading system for neuropathic pain 
55
 and this was cited by less 
than half (five out of twelve) of the studies 
3, 6, 18, 40, 42
. With reference to the IASP grading 
system, the most common working hypothesis of neuropathic pain was ‘probable’ 
3, 18, 40
. 
Three studies defined neuropathic pain using a mechanisms based classification, without 
specific reference to the IASP definition 
48, 51, 62
.  One study defined neuropathic pain with 
reference to the original IASP definition of neuropathic pain (‘pain initiated or caused by a 
primary lesion or dysfunction in the nervous system’) 
45
.  
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3.2. Prevalence 
3.2.1. Quality assessment of prevalence studies 
Seven studies reported prevalence estimates. External validity of the studies was of 
moderate to high risk of bias (see Figure 2 for a summary and Supplementary Materials 
Table S4 for full details of quality assessment of the included studies). For all seven studies, 
internal validity was at lower risk of bias than external validity. Overall, five out of the seven 
studies were deemed to be of moderate risk of bias 
3, 45, 48, 57, 62
, where further research is 
likely to have an important impact on the confidence in the prevalence estimate and may 
also change the estimate 
34
. Only two of the studies 
6, 42
 were considered to be of low risk of 
bias where further research is very unlikely to change confidence in the reported estimate 
34
.  
 
3.2.2. Prevalence estimates 
Prevalence estimates were derived from a total of 715 patients in the seven studies (Table 
3). None of the studies reported confidence intervals for the prevalence estimates and all 
studies utilised small samples. Across the studies, the prevalence of neuropathic pain in 
LBLP varied from 19% to 80%. The prevalence of neuropathic pain in LBLP varied from 19% 
in a secondary care sample of LBLP patients who consulted an outpatients spine centre with 
either sciatica or referred leg pain, to 80% in a sample of patients with LBLP associated with 
neurological signs who were recruited from either pain clinics or rheumatology settings. 
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 The prevalence of neuropathic pain was higher in populations of LBLP with sciatica 
3, 57
 
compared to mixed populations of LBLP (i.e., sciatica and referred pain) (for example, Beith 
et al 
6
 and Morsø et al 
42
).  
 
Three studies reported prevalence using case ascertainment tools and also based on clinical 
diagnosis 
3, 48, 62
. Two studies 
48
 
62
 reported that over 40% of LBLP patients in whom the pain 
was clinically diagnosed as neuropathic, presented without neuropathic pain characteristics. 
Attal et al 
3
 reported that 39% of LBLP patients with no neurological signs, reported 
neuropathic characteristics on Doleur Neuropathique en 4 (DN4) 
10
. PainDETECT 
24
 was the 
most commonly used tool to derive an estimate of prevalence; three studies provided 
estimates for “possible” or “likely” neuropathic pain that ranged from 19% 
42
 and 23% 
6
 to 
43% (for acute and subacute sciatica) and 46% (for chronic sciatica) 
57
. For all three studies 
6, 
42, 57
 the estimates for “uncertain” neuropathic pain were between 26% and 28%, showing 
less variation than the estimate of “possible” neuropathic pain. 
 
3.3. Characteristics  
3.3.1. Quality assessment of studies describing characteristics and prognosis 
Ten of the included studies 
6, 18, 25, 40, 42, 48, 51, 56, 57, 62
 underwent quality assessment, by two 
independent reviewers, using the QUIPs tool. Figure 3 summarises the risk of bias for each 
of the domains of the QUIPS tool 
29 
(see Supplementary Materials Table S5 for full details of 
quality assessment of individual studies). Three of the included studies were considered to 
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be of low risk of bias and seven at moderate risk of bias. Two of the studies 
48, 62
 that 
reported characteristics of neuropathic pain in LBLP compared to non-neuropathic pain 
were assessed to be of low risk of bias. The remaining study that was also of low risk of bias 
was a case-control study 
40
.
 
 
3.3.1. Characteristics of neuropathic pain 
The characteristics of neuropathic pain in LBLP are summarised in Table 4 and are described 
in more detail in the following section.  
3.3.3.1 Pain characteristics  
Pain intensity 
Pain intensity was reported to be higher in LBLP patients with neuropathic pain compared to 
those patients without, in the two studies where neuropathic pain was defined by case 
ascertainment tools 
42, 56
. Studies that classified neuropathic pain according to clinical 
assessment 
25, 48, 62
 showed less conclusive results; only Schafer et al 
48
 found any significant 
differences across diagnostic groups in pain intensity but still patients with “denervation” 
reported the same pain intensity as patients with “musculoskeletal” (non-neuropathic) 
LBLP.  
Pain duration and pain location 
As regards pain location, the results from four studies 
6,
 
25, 48, 51
 suggest it is likely that LBLP 
patients with neuropathic pain present with pain below the knee compared to those 
without, although it is also likely that LBLP patients with non-neuropathic pain may also 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
16
present with pain below the knee. Three studies with different sampling methods reported 
on pain duration in LBLP patients with neuropathic pain, and all described that the majority 
of patients reported long pain duration 
18, 48, 51
. Schafer et al 
48
 reported a shorter pain 
duration for clinical presentations of LBLP with neuropathic pain compared to those 
without, however there was no significant difference between all four groups. Smart et al 
51
 
reported the majority (77%) of patients with neuropathic pain had pain duration of under 
one year.  
 
3.3.3.2 Clinical examination (including self-report sensory profile) 
Two of the included studies 
25, 40
 reported the presence or absence of sensory signs 
associated with neuropathic pain, assessed either through quantitative sensory testing 
(QST) or through self-reported neuropathic characteristics 
40
. Both studies used samples of 
patients with sciatica which they considered synonymous to neuropathic pain. In addition to 
reporting the results of QST, Freynhagen et al 
25
 also reported the clinical characteristics of 
patients clinically diagnosed with either sciatica or referred leg pain. When using QST as an 
extension of normal neurological examination, LBLP patients clinically diagnosed with non-
neuropathic pain were as likely to have sensory changes as LBLP patients diagnosed with 
neuropathic pain 
25
. Description of neurological examination findings, based on this one 
study 
25
, suggest that it is likely that LBLP patients with neuropathic pain have more sensory 
deficits and changes in straight leg raise, but that sensory changes may not be a specific 
indicator of neuropathic pain. The study by Mahn et al 
40
, based on self-reported 
neuropathic characteristics, reported that pain attacks were the most common 
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characteristic of patients with sciatica and thermal induced pain was the least common.  In 
sciatica patients, based on cluster analysis of sensory profiles from self-reported 
neuropathic characteristics, five distinct subgroups of patients were reported, one subgroup 
described pain attacks and pressure induced pain. This subgroup was reported to be unique 
to patients with LBLP and not found in patients with other neuropathic clinical conditions 
such as painful diabetic neuropathy and post-herpetic neuralgia. Despite the studies by 
Mahn et al 
40
 and Freynhagen et al 
25
, not reporting on comparative patient populations 
with LBLP, they provide a useful description of the clinical characteristics and sensory profile 
of LBLP patients with neuropathic pain. 
 
3.3.3.3 Back and leg pain-related disability 
In all three studies 
42, 48, 62
, LBLP patients with neuropathic pain reported significantly higher 
levels of disability compared to patients with non-neuropathic pain. In one of the studies 
42
,
 
LBLP patients with neuropathic pain reported a median Roland Morris Disability 
Questionnaire (RMDQ) score of 18 (inter quartile range (IQR) from 14 to 20) compared to 
those patients without neuropathic pain whose median RMDQ score was 10 (IQR 7 to 15), 
this difference was reported to be clinically important. 
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3.3.3.4. Psychological characteristics 
Depression 
Moderate to severe depressive symptoms were reported in 42% of LBLP patients with 
neuropathic pain, and neuropathic pain in LBLP was associated with more severe depressive 
symptoms than in those without neuropathic pain 
56, 57
. Whether LBLP patients with 
neuropathic pain had more severe depression was not conclusive across all studies. In two 
studies with low risk of bias, Schafer et al 
48
, Walsh and Hall 
62 
reported no differences in 
depressive symptom severity across clinical presentations of LBLP with and without 
neuropathic pain. Both studies reported clinically “normal” levels of symptoms in their 
samples, as did Smart et al 
51
.  
Anxiety 
Three studies reported higher levels of anxiety in LBLP patients with neuropathic pain 
compared to non-neuropathic pain 
48, 56, 57
 and one study found no difference 
62
. Although 
Schafer et al 
48
 reported a significant difference in anxiety levels between clinical 
presentations of LBLP with and without neuropathic pain, the level of anxiety in the whole 
cohort was low, and patients with neuropathic pain reported only mild anxiety levels.  
 
Two other cohorts of patients 
51, 62
 reported comparable levels of anxiety to those reported 
by Schafer et al 
48
. In both the studies by Smart et al 
51
, Walsh and Hall 
62
 normal to mild 
levels of anxiety were reported. From the studies reporting anxiety in LBLP patients with 
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neuropathic pain, there is some evidence that LBLP patients with neuropathic pain are more 
likely to report higher levels of anxiety compared to those without neuropathic pain.  
Fear avoidance 
Fear avoidance, measured using the Fear Avoidance Beliefs Questionnaire (FABQ) 
61
, was 
investigated in two studies 
48, 62
. Significant differences across clinical presentations of LBLP 
with and without neuropathic pain were reported in the physical activity sub-scale but not 
in the work sub-scale, in one of the studies 
62
. The study by Schafer et al 
48
 did not find any 
differences in fear avoidance across clinical presentations of LBLP with and without 
neuropathic pain.  
 
3.3.3.5. Health related quality of life 
Three studies, all with moderate risk of bias, reported on aspects of quality of life and 
general health. Tutoglu et al 
56
 used domains of the Short Form health survey (SF-36) 
64
 to 
report on quality of life. Morsø et al 
42
 used a self-report numerical rating scale (0-10)  for 
general health, and one further study 
40
 reported on sleep using the medical outcome scale 
30
. Morsø et al 
42
 found that general health in LBLP patients with neuropathic pain was 
worse than in those with non-neuropathic pain. Similar findings were reported by Tutoglu et 
al 
56
 who found that all seven dimensions of the SF-36 (physical function, physical role, 
emotional role, social function, mental health, energy/vitality and pain) were worse for LBLP 
patients with neuropathic pain compared to those without. Mahn et al 
40
 reported that 
sleep was optimal in 37% of LBLP patients with neuropathic pain, with these patients also 
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reporting sleep disturbance and somnolence. There was some consistent evidence that LBLP 
patients with neuropathic pain presented with poorer quality of life compared to those 
without neuropathic pain, however evidence for sleep in this patient population was 
limited.  
 
3.3.3.6 Medication use 
Two studies 
25, 42
, with moderate risk of bias, reported that LBLP patients with neuropathic 
pain use significantly more analgesia than LBLP patients with non-neuropathic pain. They 
are also more likely to use opioid medications compared to LBLP patients without 
neuropathic pain. Both patient groups report similar use of non-steroidal anti-inflammatory 
drugs 
25
. Amongst these two studies there is consistent low level evidence that patients with 
neuropathic pain are managed with more analgesia than those with non-neuropathic pain. 
It is not clear from these studies whether medication use is a feature of neuropathic pain or 
a result of the sampling methods used, or whether the use of medication was associated 
with improved outcomes in LBLP patients with neuropathic pain.  
 
3.4. Prognosis 
Two studies reported longitudinal data 
42, 48
, one of which described overall prognosis 
(clinical course) 
42
. Schafer et al 
48
 reported on patient outcomes following treatment 
patients were clinically assessed to have LBLP related to neuropathic pain, both with and 
without neuropathic characteristics (patients were classified into one of four groups, 
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neuropathic sensitisation, denervation, peripheral nerve sensitisation or musculoskeletal). 
They reported that the greatest improvement in outcomes was in LBLP patients with 
peripheral nerve sensitisation, and the least improvement in LBLP patients with neuropathic 
sensitisation. A number of potential limitations were acknowledged by the authors 
48
: short 
follow-up time (mean duration of treatment varied from 25 days to 33 days), lack of control 
group, and a large proportion of ineligible patients. Neither the study by Schafer et al 
48
 nor 
the one by Morsø et al 
42
 provided any evidence of prognostic factors of neuropathic pain in 
LBLP.  
 
Morsø et al 
42
 followed up LBLP patients at three and twelve months (outcomes were back 
and leg pain intensity, leg and back-related disability and self-reported general health) and 
showed that for both patient groups (with neuropathic and without neuropathic pain) most 
outcomes improved over time (see Table 5). At three and twelve months, LBLP patients with 
neuropathic pain remained worse compared to those with non-neuropathic pain in all 
outcomes except back pain intensity. 
 
4. Discussion 
This is the first systematic review to synthesise available published evidence about the 
prevalence, characteristics and prognosis of LBLP patients with neuropathic pain. 
Heterogeneity of the included studies prevented meta-analysis, but comparisons between 
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studies and settings were still possible in relation to study design, quality and strengths and 
weaknesses.  
 
4.1. Prevalence 
In this systematic review, prevalence estimates were extrapolated from data from seven 
studies that were based in either primary care or in clinical settings that patients could 
feasibly have accessed directly, and therefore the population samples were considered to 
be similar. Overall prevalence reported in this systematic review varied widely. This is not 
the first systematic review to report variation in prevalence estimates, variation is reported 
in reviews of neuropathic pain populations in the general population (irrespective of clinical 
condition)
 59
 and in populations seeking care for non-specific LBP 
22, 35
. Variation in the 
reported neuropathic pain prevalence estimates in this systematic review is likely in part to 
be a function of the patient sample in each study, as all included studies had small sample 
sizes and the uncertainty around the prevalence estimate from each study remains 
unknown as the studies did not report confidence intervals. Another reason for variation is 
likely to be due to the methods used by each study for defining neuropathic pain cases. 
 
Variation in prevalence due to differences in the case ascertainment tools is reasonable to 
consider 
59
. In a study included in this review, Walsh and Hall 
62
 reported prevalence of 33% 
(15 out of 45 patients) using S-LANSS but in a different study using the same cohort (both 
studies were conducted at the same time) they reported a prevalence of 42% (19 out of 45 
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patients) when using the DN4. The later study by Walsh and Hall 
62
 demonstrates that case 
ascertainment tools may identify different patients due to subtle differences in the tools’ 
questions and the presence or absence of clinical examination tests within each tool 
60
. 
Identification of LBLP subgroups on the basis of the presence or absence of neuropathic 
characteristics is supported by previous research of patients with LBLP and other 
neuropathic pain conditions such as painful diabetic neuropathy and post-herpetic neuralgia 
5
. Whether different subgroups of LBLP patients with neuropathic pain have different 
characteristics is not clear from the results of this systematic review but it is an implication 
for the development of targeted treatments in this patient population. The variation in 
prevalence reported in this systematic review in part, reflects inconsistency in defining cases 
of neuropathic pain both in research and in clinical practice. The results of this systematic 
review show that LBLP patients with sciatica show higher prevalence of neuropathic pain 
than those samples with mixed cases of sciatica and referred pain, but not all patients with 
sciatica have neuropathic type of pain, whereas some patients have referred leg pain which 
is neuropathic. These results support the argument for the presence of distinct subgroups of 
LBLP patients with neuropathic pain. It is important to determine whether those LBLP 
patients with neuropathic pain present with worse morbidity compared to those without. 
 
4.2. Characteristics and prognosis 
The included studies in this systematic review reported some consistent evidence for worse 
back and leg pain-related disability in LBLP patients with neuropathic pain. In part, this is 
consistent with the wider literature on neuropathic pain, patients with neuropathic pain 
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have been reported to have worse morbidity than those without. Patients with neuropathic 
pain in the general population, irrespective of clinical condition, have been reported to have 
poor quality of life 
54
. Depression and anxiety symptoms were commonly reported in 
patients with uncontrollable neuropathic pain 
17
. The results also mirror findings from 
studies of the broader population of patients with neuropathic pain in LBP, where disability 
24, 46
, quality of life 
33
, pain intensity 
24, 47
 depression and anxiety 
24
 are worse in patients with 
neuropathic pain.  
 
Similarly, eight of the studies included in this review, albeit at moderate risk of bias, found 
that LBLP patients with neuropathic pain reported more severe back and leg pain related 
disability, health related quality of life, pain intensity, depression and anxiety than those 
without neuropathic pain. The two remaining studies 
48, 62
, assessed to be of low risk of bias, 
reported fewer differences in pain intensity, depression and anxiety between patients with 
and without neuropathic pain.  Unlike the other included studies, these two used clinical 
assessment to identify cases of neuropathic pain in LBLP patients. Both 
48, 62
 however, had 
small samples across four groups and it may be argued they lacked the power to detect any 
differences in characteristics between groups. In clinical practice, especially in settings such 
as primary care, the use of case ascertainment tools is rare and neuropathic pain is more 
commonly defined using clinical history and examination. Overall, it is not clear whether 
back and leg pain-related morbidity in patients with neuropathic pain is due to the use of 
different methods of defining and identifying cases of neuropathic pain or whether it is due 
to differences in study design and perhaps methodological quality.  
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Individual components from history taking (pain location) and neurological clinical 
examination were reported in a number of studies included in this review. In four of the 
studies 
6, 25, 48, 51
, pain below the knee was associated with neuropathic pain, but not all 
patients with neuropathic pain had below knee pain. This finding, that individual 
components of clinical history and examination (pain location, neurological findings) are not 
specific indicators of neuropathic pain, is supported by the wider literature on LBP patients 
with neuropathic pain. Freynhagen et al 
25
 reported that patients with non-neuropathic pain 
have sensory deficits and positive findings on neural tension tests. The finding that 
neurological signs and deficits might not be exclusive to patients with neuropathic pain is 
supported by Attal et al 
3
 who reported that patients with neuropathic characteristics were 
more typical of sciatica but neuropathic characteristics were not restricted to patients 
clinically classified as having sciatica. Conversely, a subgroup of patients with a clinical 
diagnosis of sciatica have no features of neuropathic pain 
40, 48, 62
, and patients with referred 
leg pain may have features of pain that is neuropathic. The underlying mechanism of LBLP is 
thought to be mixed, where neuropathic and nociceptive mechanisms coexist, but in some 
circumstances inflammatory mechanisms can produce similar characteristics to neuropathic 
mechanisms (for example, pain attacks and allodynia). The results of this review suggest 
that there may be subgroups of LBLP patients with or without neuropathic pain but it is not 
clear whether these subgroups differ in their future clinical outcomes or in their response to 
targeted treatments. 
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It is physiologically feasible that underlying nociceptive stimuli causing LBLP, for example 
degeneration of an intervertebral disc, over time may involve microscopic nerve fibres 
4
. 
This involvement may lead to secondary lesions of the nerve fibres and give rise to 
neuropathic signs and symptoms in patients who initially presented with nociceptive pain. 
Conversely, neuropathic pain is often assumed to persist but it is not known whether 
patients who initially present with neuropathic pain continue to have signs and symptoms of 
neuropathic pain over time. In this systematic review, there was inconclusive evidence, from 
three studies, that patients with neuropathic pain report longer pain duration.  
 
Only one of the two identified studies with longitudinal data described prognosis in LBLP 
patients with neuropathic pain 
42
. Neither study with longitudinal data reported whether 
LBLP patients with or without neuropathic pain at baseline, might change in terms of 
presence or absence of signs and symptoms of neuropathic pain over time. The study by 
Morsø et al 
42
 found that both patients with and without neuropathic characteristics 
improved over time, but that LBLP patients with neuropathic characteristics improved to a 
lesser extent in terms of disability, pain and self-reported general health compared to those 
without. It is not clear from their study 
42
 whether LBLP may change from a neuropathic 
state to non-neuropathic and vice versa, and they did not investigate prognostic factors 
associated with recovery from pain or disability in LBLP patients with neuropathic pain. 
Prognostic research offers the opportunity for clinicians and patients to understand what is 
going to happen to pain and other symptoms, in the future. The apparent absence of 
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prognostic research in LBLP patients with neuropathic pain highlights a gap in the literature 
warranting future research. 
 
This systematic review shows low levels of agreement on the characteristics of LBLP with 
neuropathic pain derived from cross-sectional studies, and it highlights a gap in the evidence 
in the description of these patients in primary care. Cross-sectional studies can provide valid 
evidence of associations for stable characteristics, such as gender. In the context of this 
systematic review, depression and anxiety is, in some studies, associated with neuropathic 
pain in LBLP patients, but depression is also linked to the number of pain locations 
26
. It is 
not clear from this systematic review whether LBLP patients with neuropathic pain have 
more symptoms of depression or anxiety or whether this is a spurious finding confounded 
by the number of pain locations. One of the key weaknesses of cross-sectional data is that 
they do not offer any temporal relationship and thus prognosis can only be derived from 
longitudinal research. Identifying subgroups of LBLP patients with or without neuropathic 
pain and investigating the prognosis of these patients is important in order to describe and 
understand the likelihood of different outcomes 
15
. 
 
4.3. Strengths and limitations 
This review used a comprehensive systematic approach that was applied throughout the 
study. An exhaustive search strategy was developed and applied using six search engines. 
Additional searches and citation tracking were also executed, however some supporting 
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evidence may have been missed, for example, studies not published as full text. A further 
limitation was the inability to provide pooled estimates of prevalence and characteristics, 
because of heterogeneity between studies. An important strength of this review was the 
use of two quality assessment tools, one for prevalence studies and one for the studies on 
characteristics and prognosis. 
 
4.4. Implications for research and clinical practice 
This systematic review highlights the need for high quality research on the epidemiology of 
neuropathic pain in LBLP patients in clinical settings such as primary care, where the 
majority of LBLP patients consult and are treated. There is a clear gap in the evidence of 
both cross-sectional description of baseline characteristics as well as the prognosis of 
neuropathic pain in this patient population. Currently there is an absence of available 
evidence in this important patient group. The review also identified that there may be 
different subgroups of LBLP patients with or without neuropathic characteristics. It is 
important to determine whether the prognosis of these different groups of LBLP patients 
differ over time to inform both clinicians and LBLP patients. 
 
4.5. Conclusions 
This systematic review of LBLP patients with neuropathic pain, found a wide variation in 
reported prevalence estimates, some evidence of higher levels of morbidity in LBLP patients 
with neuropathic pain compared to those without, and evidence that there may be 
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subgroups of LBLP patients with and without neuropathic pain in both those clinically 
diagnosed with sciatica or referred leg pain. Limitations in the available literature have been 
identified and discussed, and applying the findings of this review to current clinical practice 
in primary care and in settings similar to primary care should be done with caution. Future 
research investigating the prognosis of LBLP patients with or without neuropathic pain is 
likely to inform decision making in clinical practice, it may also contribute to the timely 
delivery of targeted treatment interventions, such as specific medications, for this group of 
patients.  
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Table and Figure Legends 
Figure 1. Flow chart of systematic search and study selection (adapted from the PRISMA 
flow chart) 
41
 
Figure 2. Summary of quality assessment 
34
 (described as a proportion (%) of studies by risk 
of bias) of the seven included studies used to derive prevalence 
Figure 3. Summary of quality assessment 
29
 (described as a proportion (%) of studies by risk 
of bias) of the ten included studies used to describe characteristics and prognosis 
Table 1. Eligibility criteria for study selection, detailing an itemised description of the 
inclusion and exclusion criteria for this review 
Table 2.  Summary of all 12 studies included in the systematic review  
Table 3.  Studies providing prevalence estimates of neuropathic pain in low back-related leg 
pain, grouped by method of establishing neuropathic pain 
Table 4. Studies describing characteristics of neuropathic pain in low back-related leg pain 
(LBLP) 
Table 5. Study by Morsø et al 
42
 showing overall prognosis (using results obtained through 
personal communication with the author) of neuropathic pain in low back-related leg pain 
(n=145) 
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Table 1. Eligibility criteria for study selection, detailing an itemised description of the 
inclusion and exclusion criteria for this review.  
Published studies were included if they fulfilled any of the following criteria: 
• Cohort study, case control, cross-sectional study designs available as full text 
• Human participants, over 18 years 
• Clearly defined groups of patients with and without neuropathic pain (for example, 
through using neuropathic case ascertainment tools, clinical history and clinical 
examination) 
• Participants with low back-related leg pain 
• Primary care, or clinical settings identified as the first point of contact for patients with 
low back-related leg pain where assessment and treatment of the population could be 
applied in primary care. Including: 
o occupational settings 
o physiotherapy outpatients, general practice, osteopathic or chiropractic clinics 
o secondary care 
• Data reporting prevalence or incidence, clinical course of the condition, characteristics 
associated with prognosis of the condition (for example, severity of pain, duration of 
pain, back/leg pain disability) 
Published studies were excluded if they fulfilled any of the following criteria: 
• Intervention studies (e.g. RCTs), case studies, small case series, systematic reviews, 
guidelines and medical reference 
• Animal subjects 
• Specific neuropathic pain conditions. Including: 
o diabetes, cancer, HIV, multiple sclerosis, Guillain Barre syndrome, spinal cord 
injuries 
• Low back pain patients where related leg pain is not clearly defined  
•  Populations with specific back pain conditions. Including: 
o pregnant women, post-surgical patients, ankylosing spondylitis, rheumatoid 
arthritis, lumbar spinal stenosis, herniated discs, failed back surgery syndrome, 
osteoporosis, serious spinal pathology (cauda equina, malignancy, fractures, 
spinal infection) 
• Other settings. Including:  
o Settings where spinal surgery, spinal cord stimulation, caudal epidural or facet 
joint injections or spinal nerve root blocks were carried out 
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Table 2.  Summary of all 12 studies included in the systematic review  
Study 
author, date 
and country 
Study 
design  
LBLP 
Population  
Population  
(Number in 
sample, 
proportion of 
male, mean age 
((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain 
55
  
Setting:  
Attal et al. 
(2011)
3
, 
France 
Cross-
sectional 
Mixed
*
 LBLP 
> 3 months 
symptom 
duration and 
VAS ≥4/10 
(QTSFD
†
 
groups 2 to 
4) 
N = 92 
41% M 
Age: 54 (14) 
Yes DN4 QTSFD group 
4: Probable 
MDT pain clinics 
or rheumatology 
centres 
Beith et al. 
(2011)
6
, UK 
Cross-
sectional 
Mixed
*
 LBLP N=227 
(NR)% M  
Age: NR 
Yes PainDETECT Possible Physiotherapy 
referrals in 
primary care and 
secondary care 
Defrin et al. 
(2014)
18
 
Israel 
Case 
control 
Sciatica > 3 
months with 
radicular 
pain into the 
leg 
N = 74 
47%  M  
Age: 66 (NR) 
No 
(neuropathic 
pain in LBLP 
with vs 
without 
allodynia) 
Clinical history 
including imaging 
and 
electrophysiology 
Probable Pain clinic 
Freynhagen Case Sciatica Radicular pain
ǁ
:  Yes Clinical history, Not defined Pain medicine, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Study 
author, date 
and country 
Study 
design  
LBLP 
Population  
Population  
(Number in 
sample, 
proportion of 
male, mean age 
((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain 
55
  
Setting:  
et al. (2008) 
25
, Germany 
control  (chronic 
unilateral leg 
pain)  
N = 15, 42% M 
Age: 54 (16)  
Pseudoradicular 
pain: 
N = 12, 44% M 
Age: 52 (16) 
examination and 
imaging/ 
electrophysiology 
where indicated 
neurology and 
neurosurgery 
setting 
Mahn et al. 
(2011), 
40
, 
Germany 
Cross-
sectional 
Sciatica  N=2094 
42% M  
Age: 59 (14) 
No History, clinical 
assessment, leg 
pain worse than 
back pain  
Probable 450 outpatient 
centres (primary 
and secondary 
care) 
Morsø et al. 
(2011) 
42
, Denmark 
Cross-
sectional 
with follow 
up data 
Mixed
*
 LBLP 
> 3 months 
and <12 
months  
N=145 
39% M  
Age: 50 (15) 
Yes  PainDETECT Possible Outpatient spine 
centre in 
Secondary care 
Ouédraogo 
et al. (2012) 
45
, 
Burkina 
Faso 
Cross-
sectional  
Mixed
* 
LBLP N = 66  
(NR)%M  
Age: NR 
Yes  DN4  Not defined Rheumatology, 
Neurology and 
Neurosurgery 
clinics 
Schafer et 
al. (2011) 
48
, Germany 
Cross-
sectional 
follow up 
Mixed
*
 LBLP 
> 6  weeks 
and NRS 
 N=74  
40% M  
Age: 48 (13) 
Yes  LANSS and 
clinical 
assessment to 
Not defined MDT pain clinics 
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Study 
author, date 
and country 
Study 
design  
LBLP 
Population  
Population  
(Number in 
sample, 
proportion of 
male, mean age 
((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain 
55
  
Setting:  
data >3/10
 ‡
 determine neural 
related leg pain 
classification 
Smart et al. 
(2012) 
51
, 
UK & 
Ireland 
Cross-
sectional  
Mixed
*
 LBP 
+/- leg pain
§
 
 
 N=474  
44% M  
Age: 44 (NR) 
No  Clinical indicators 
derived from a 
mechanisms 
based 
classification 
system  
Not defined 4 hospital sites: 
back pain clinics 
(assessments 
done by 
physiotherapists) 
Tutoglu et 
al. (2015) 
56
 Turkey 
Case 
control  
Sciatica  N=73 
40% M  
Age: for sciatica 
group with 
neuropathic 
pain: 53 (10),  
For sciatica 
group without 
neuropathic 
pain: 50 (7) 
Yes
 ¶
  DN4 Not defined Physical 
medicine and 
rehabilitation 
outpatient clinic 
Uher and 
Bob (2013), 
57
,  
Cross-
sectional  
Sciatica  N=66 
42% M 
Age: 58 (NR) 
Yes  PainDETECT 
(Czech version) 
Not defined Neurology 
Inpatients 
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Study 
author, date 
and country 
Study 
design  
LBLP 
Population  
Population  
(Number in 
sample, 
proportion of 
male, mean age 
((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain 
55
  
Setting:  
Czech 
Republic 
Walsh and 
Hall (2009) 
62
, Ireland 
Cross-
sectional 
Mixed
*
 LBLP
‡
 N=45 
49% M 
Age: 46 (11) 
Yes S-LANSS and 
clinical 
assessment to 
determine 
neuropathic 
related leg pain  
Not defined Back pain clinic 
DN4, Doleur Neuropathique en 4 
10
. L4, L5, S1, lumbar spinal nerve roots. LANSS, Leeds Assessment of Neuropathic Symptoms and 
Signs 
7
. LBLP, low back-related leg pain. M, male. MDT, multi-disciplinary team. MRI, magnetic resonance imaging. NR, not reported. 
NRS, numerical rating scale. PainDETECT, 
24
. QTSFD, Quebec task force classification of spinal disorder. S-LANSS, Self-report version 
of the Leeds Assessment of Neuropathic Symptoms and Signs 
8
. VAS, visual analogue scale. 
* 
Mixed LBLP: heterogeneous samples of LBLP that include both clinical diagnosis of sciatica and referred leg pain. 
† 
QTSFD, classified as group 2 to 4: Group 2, pain in the lumbar area with proximal radiation (i.e., to lower limb, but not beyond the 
knee). Group 3, pain in the lumbar area radiating below the knee and no neurological signs. Group 4, pain in the lumbar area 
radiating towards the foot in a dermatomal distribution, associated with sensory deficits or other neurological signs.  
‡
 Diagnostically classified into one of four groups, neuropathic sensitisation, denervation, peripheral nerve sensitisation or 
musculoskeletal. 
§
Diagnostically classified into one of three groups, peripheral neuropathic pain (PNP), central neuropathic pain and nociceptive pain. 
PNP was made up of 91% LBLP and 9% predominant low back pain; central neuropathic and nociceptive pain were predominantly 
low back pain (61% and 82% respectively). 
ǁ
 In this study, radicular pain was considered synonymous to neuropathic pain. 
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Study 
author, date 
and country 
Study 
design  
LBLP 
Population  
Population  
(Number in 
sample, 
proportion of 
male, mean age 
((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain 
55
  
Setting:  
 ¶ 
Grouped as sciatica and neuropathic pain, sciatica and non-neuropathic pain and a control group.
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Table 3.  Studies providing prevalence estimates of neuropathic pain in low back-related leg 
pain, grouped by method of establishing neuropathic pain.  
 
Study  Case ascertainment 
tool used to derive 
neuropathic pain 
Numerator used for calculation of prevalence Prevalence of 
neuropathic 
pain (%)
*
 
3
  DN4 LBLP  49 
QTSFD
† 
group 4  80 
QTSFD
† 
group 3  39 
QTSFD
†
 group 2  15 
45
 DN4 LBLP  61 
48
 
  
LANSS  LBLP with LANSS ≥12 and clinical examination 
confirming neuropathic pain 
26 
LBLP with clinical examination confirming neuropathic 
pain but with LANSS <12 
47 
62
  S-LANSS LBLP with S-LANSS ≥12 and clinical examination 
confirming neuropathic pain 
33 
LBLP with clinical examination confirming neuropathic 
pain but with S-LANSS <12 
40 
42
 PainDETECT LBLP with “possible” neuropathic pain component 19 
LBLP with “uncertain” pain classification  26 
57
  PainDETECT Acute and sub-acute sciatica with “possible” 
neuropathic pain component 
43 
Acute and sub-acute sciatica with “uncertain” pain 
classification  
28 
Chronic sciatica with “possible” neuropathic pain 
component 
46 
Chronic sciatica with “uncertain” pain classification 27 
6
 
 
PainDETECT LBLP with “possible” neuropathic pain component 23 
LBLP with “uncertain” pain classification 27 
DN4, Doleur Neuropathique en 4 
10
. LANSS, Leeds Assessment of Neuropathic Symptoms and Signs 
7
. 
LBLP, Low back-related leg pain. PainDETECT, 
24
. QTSFD, Quebec task force classification of spinal 
disorder. S-LANSS, Self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs 
(Bennett et al., 2005). 
*
 The denominator is total number (N) of LBLP in the sample. 
† 
QTSFD, classified 
as group 2 to 4: Group 2, pain in the lumbar area with proximal radiation (i.e., to lower limb, but not 
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beyond the knee). Group 3, pain in the lumbar area radiating below the knee and no neurological 
signs. Group 4, pain in the lumbar area radiating towards the foot in a dermatomal distribution, 
associated with sensory deficits or other neurological signs. 
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Table 4. Studies describing characteristics of neuropathic pain in low back-related leg pain (LBLP) 
 
Characteristic 
associated 
with 
neuropathic 
pain 
Study Outcome measure 
used 
LBLP patients with neuropathic pain LBLP with non-
neuropathic pain 
Reported P  
Pain intensity 
25
  
 
NRS (unspecified 
whether for back or 
leg) 
Mean 6.4 (SD 1.8) Mean 5.3 (SD 2.3) 0.19 
42
  
 
NRS leg pain 
 
Leg pain median 8.0, IQR 5.3 to 8.0 
 
Leg pain median 4.0, IQR 
1.0 to 6.0 
0.012 
NRS back pain Back pain median 7.0, IQR 5.0 to 8.8 Back pain median 6.0, IQR 
4.0 to 7.0 
0.000 
48
  
 
NRS (unspecified 
whether back or leg) 
Neuropathic sensitisation mean 5.8 (SD 
1.7); peripheral nerve sensitisation mean 
5.3 (SD 1.7); denervation mean 4.6 (SD 
1.5) 
Mean 4.6 (SD 1.4) 0.031 
56
  
 
VAS (unspecified 
whether back or leg) 
Mean 8.0 (SD 1.6) Mean 6.6 (SD 3.4)  0.033 
62
  
 
VAS (unspecified 
whether back or leg) 
Neuropathic sensitisation mean 6 (SD 3); 
peripheral nerve sensitisation mean 7 (SD 
2); denervation mean 6 (SD 3)  
Mean 5 (SD 3) 0.23 
Pain location 
6
  % reporting pain 
below the knee 
79% of LBLP patients with possible 
neuropathic pain, 74% of LBLP with 
uncertain pain 
57%  n/a 
25
   
 
% reporting pain in 
the leg 
Radiating pain below the knee: in S1 
dermatomal distribution 25%, in L5 
dermatomal distribution 50%, to L4 17%, 
Radiating pain to the 
gluteal region or thigh (but 
not below knee) 100% 
n/a 
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Characteristic 
associated 
with 
neuropathic 
pain 
Study Outcome measure 
used 
LBLP patients with neuropathic pain LBLP with non-
neuropathic pain 
Reported P  
to L4 & L5 8% 
48
  
 
% reporting pain 
below knee 
Neuropathic sensitisation 80.0%, 
peripheral nerve sensitisation 88.9%, 
denervation 71.4% 
73.7% 0.71 
51
  Predominant pain 
location 
Back 9%, back/thigh 19%, unilateral leg 
pain below knee 59%, back and unilateral 
leg pain below knee 11%, bilateral leg pain 
below knee 1% 
n/a n/a 
Pain duration 
18
 
†
 Years With allodynia mean 5.7  (SD 5.6) 
Without allodynia mean 2.7  (SD 2.9) 
n/a n/a 
48
  
 
Current episode 
(months)  
Neuropathic sensitisation mean 7.0 (SD 
18.4); peripheral nerve sensitisation mean 
6.0 (SD 12.5); denervation mean 7.3 (SD 
11.3) 
Mean 10.6 (SD 12.2) 0.76 
51
  Current episode 0 to 12 weeks (34%), 4 to 12 months 
(43%), 1 year and over (23%) 
n/a n/a 
Back and leg 
pain-related 
disability 
42
  
 
RMDQ Median 18, IQR 14 to 20  Median 10, IQR 7 to 15 0.000 
48
  RMDQ Neuropathic sensitisation mean 10.5 (SD 
4.0); peripheral nerve sensitisation mean 
5.3 (SD 1.7); denervation mean 8.7 (SD 
4.5)  
Mean 6.5 (SD 3.3) 0.014 
62
 ODI 
 
 
Neuropathic sensitisation mean 37 (SD 5); 
peripheral nerve sensitisation mean 52 
(SD 17); denervation mean 32 (SD 10) 
Mean 30 (SD 10) 0.001 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Characteristic 
associated 
with 
neuropathic 
pain 
Study Outcome measure 
used 
LBLP patients with neuropathic pain LBLP with non-
neuropathic pain 
Reported P  
Psychological 
characteristics 
(depression) 
40
 
†
 PH9 None (23%), mild (35%), moderate (37%), 
severe (5%). 
n/a n/a 
48
  
 
HADS Neuropathic sensitisation mean 9.1 (SD 
4.6); peripheral nerve sensitisation mean 
4.9 (SD 2.5); denervation mean 5.6 (SD 
3.6) 
Mean 7.2 (SD 4.0) 0.37 
51
  HADS Mean 7.0 (SD 4.4) n/a n/a 
56
 BDI Mean 20.9 (SD 12.4) Mean 5.9 (SD 5.4) <0.001 
57
  BDI-II Neuropathic pain group mean 14.4 (SD 
9.2); ambiguous pain mean 12.9 (SD 7.6) 
Mean 9.3 (SD 5.0) <0.01 
62
  HADS Neuropathic sensitisation mean 7 (SD 4); 
peripheral nerve sensitisation mean 8 (SD 
4); denervation mean 5 (SD 3) 
Mean 5 (SD 3) 0.12 
Psychological 
characteristics 
(anxiety) 
48
  HADS Neuropathic sensitisation mean 9.1 (SD 
4.6); peripheral nerve sensitisation mean 
4.9 (SD 2.5); denervation mean 5.6 (SD 
3.6) 
Mean 7.2 (SD 4.0) 0.013 
51
  HADS Mean 7.5 (SD 4.4) n/a n/a 
56
  BAI Mean 10.2 (SD 10.8) Mean 3.1 (SD 3.7) <0.001 
57
  SAS Neuropathic pain  mean 42.9 (SD 8.5); 
ambiguous pain mean 39.2 (SD 7.3) 
Mean 35.8 (SD 8.5) <0.01 
62
  HADS Neuropathic sensitisation mean 9 (SD 4); 
peripheral nerve sensitisation mean 10 
(4); denervation mean 7 (SD 3) 
Mean 7 (SD 2) 0.14 
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Characteristic 
associated 
with 
neuropathic 
pain 
Study Outcome measure 
used 
LBLP patients with neuropathic pain LBLP with non-
neuropathic pain 
Reported P  
Psychological 
characteristics 
(fear 
avoidance) 
48
  FABQ Neuropathic sensitisation mean 39.1 (SD 
19.1); peripheral nerve sensitisation mean 
36.4 (SD 18.8); denervation mean 34.3 (SD 
19.0) 
Mean 29.8 (SD 21.2) 0.51 
62
  FABQ - Physical 
activity 
Neuropathic sensitisation mean 16 (SD 3); 
peripheral nerve sensitisation mean 20 
(SD 4); denervation mean 12 (SD 5) 
Mean 18 (SD 3) 0.001 
62
  FABQ - Work Neuropathic sensitisation mean 22 (SD 
11); peripheral nerve sensitisation mean 
21 (SD 11); denervation mean 21 (SD 13) 
 Mean 22 (SD 13) 0.99 
Health related 
quality of life 
42
  Self-rated general 
health (0-10) 
Median 2, IQR 1 to 3 Median 3, IQR 2 to 4 0.001 
56
   SF-36  physical 
function   
Mean 44.3 (SD 26.3)  Mean 77.7 (SD 24.7) <0.001 
 SF-36  physical role Mean 1.9 (SD 40.8) Mean 56.8 (SD 43.2) <0.001 
 SF-36 emotional role Mean 35.2 (SD 42.9) Mean 64.0 (SD 42.6) <0.001 
 SF-36 social function Mean 36.7 (SD 42.9) Mean 53.7 (SD 18.1) <0.001 
 SF-36 mental health Mean 47.2 (SD 13.5) Mean 55.1 (SD 11.6) <0.001 
 SF-36 energy/vitality Mean 36.8 (SD 19.1) Mean 51.1 (SD 13.4) <0.001 
 SF-36 pain Mean 37.3 (SD 18.9) Mean 55.0 (SD 22.8) <0.001 
 SF-36 general health Mean 36.1 (SD 13.3) Mean 40.8 (SD 10.9) <0.001 
Health related 
quality of life 
(sleep) 
40 †
  Sleep (MOS sleep 
scale)
 ††
 
Disturbance mean 45 (SD 25), somnolence 
mean 40 (SD 22), sleep adequacy mean 51 
(SD 28). Optimal sleep 37% 
n/a n/a 
Other 
25
  Clinical examination  Positive neural tension tests (proportion Positive straight leg raise n/a 
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Characteristic 
associated 
with 
neuropathic 
pain 
Study Outcome measure 
used 
LBLP patients with neuropathic pain LBLP with non-
neuropathic pain 
Reported P  
characteristics  of sample, 42%), positive straight leg raise 
(50%), reflex deficit (25%), sensory deficit 
(58%), motor deficit (25%) 
(proportion of sample, 
13%), sensory deficit (20%) 
 
40
 Self-reported 
neuropathic 
characteristics 
Burning (25%), prickling (26%), allodynia 
(10%), attacks (32%), thermal induced 
pain (8%), numbness (16%), pressure 
induced pain (21%) 
n/a n/a 
† 
Characteristics derived from case control studies and the reported associations are for LBLP patients with neuropathic pain only.
 
††
 Sleep disturbance, somnolence and sleep adequacy are reported on a VAS of 0 to 100. 
BAI, Beck anxiety inventory. BDI, Beck depression inventory. BDI-II, Beck depression inventory (Czech version). FABQ, Fear avoidance 
beliefs questionnaire. IQR, interquartile range. LBLP, low back-related leg pain. MOS, Medical outcome study.  n/a, not applicable.  
NRS, numerical rating scale. NSAID, non-steroidal anti-inflammatory drug. ODI, Oswestry Disability Index. PH9, patient health 
questionnaire. RMDQ, Roland Morris Disability Questionnaire. SAS, Zung self-rating anxiety scale (Czech version). SD, standard 
deviation. SF-36, The Short Form (36) Health Survey. TAS-20, Toronto alexithymia scale (Czech version) where alexithymia is defined as 
being functionally unaware of your emotions. VAS, visual analogue scale. 
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Table 5. Study by Morsø et al 
42
 showing overall prognosis (using results obtained through personal communication with the author) of 
neuropathic pain in low back-related leg pain (n=145) 
Outcome LBLP patients with neuropathic pain
†
 
 
LBLP patients with non-neuropathic pain
†
 
 
 
Difference in median values 
between neuropathic and 
non-neuropathic pain patients 
(shown as reported P value) 
Baseline 3 months 12 months Baseline 
 
3 months 12 months Baseline 3  
months 
12 
months 
Median Median P Median P Median Median P Median P P P P 
Back pain 
intensity  
(NRS 0-10) 
7.0 5.2 0.011 4.3 0.001 6.0 4.0 0.002 4.8 0.003 0.012 0.054 0.214 
Leg pain 
intensity 
(NRS 0-10) 
8.0 6.0 0.007 4.0 0.002 4.0 2.3 0.023 1.7 0.032 >0.001 0.001 0.022 
Leg and back 
pain related 
disability  
(RMDQ 0-23) 
17.5 14.0 0.016 13.5 0.008 10.0 9.0 0.001 5.0 >0.001 >0.001 >0.001 0.009 
Self-reported 
general 
health
††
 
2.0 3.0 0.072 3.0 0.012 3.0 4.0 >0.001 4.0 0.004 0.001 0.010 0.033 
†
 PainDETECT was used to ascertain neuropathic pain status 
††
 Self-reported general health was rated on a 7 point Likert scale where “unbearable” was scored as 0 and “excellent” as 7 
NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire  
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Figure 1. Flow chart of systematic search and study selection (adapted from the PRISMA flow 
chart) 
41
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Titles screened after duplicates removed 
(n = 18,027) 
Titles and abstracts 
screened (n = 556) 
In
cl
u
d
e
d
 
Records excluded  
(n = 17,471) 
E
li
g
ib
il
it
y
 
Records identified through database searching 
EMBASE 10,853 MEDLINE 6,250  
Web of science 5,123, CINAHL 1,449  
Trip 984, AMED 339 
(n = 24,948) 
Additional records identified 
through other sources  
(n = 3) 
Full-text articles excluded, with reasons (n=76): 
• Neuropathic pain not measured (n=4) 
• Neuropathic pain related to specific health condition 
(n=3) 
• Population not LBP (n=23), or LBLP (n=12), or were a 
specific LBLP population (for example, failed back 
surgery syndrome) (n=6) 
• Tertiary care settings (n=2) 
• Outcome not of interest to the study (n=5) 
• Study design not appropriate or not available (n=21) 
Full-texts included for 
qualitative synthesis  
(n = 12) 
Full-text articles assessed for 
eligibility (n= 88) 
Records excluded  
(n = 468) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Figure 2. Summary of quality assessment 
34
 (described as a proportion (%) of studies by risk 
of bias) of the seven included studies used to derive prevalence.  
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Figure 3. Summary of quality assessment 
29
 (described as a proportion (%) of studies by risk 
of bias) of the ten included studies used to describe characteristics and prognosis  
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Highlights  
• 12 studies were included in the review 
• Prevalence estimates of neuropathic pain in LBLP patients varied from 19% to 80% 
• Consistent evidence for worse disability in LBLP patients with neuropathic pain vs 
those without 
• Based on one study, prognosis was worse for LBLP patients with neuropathic pain  
• No evidence found on characteristics associated with prognosis (prognostic factors)  
 
